Last Updated: June 17, 2026

CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE Drug Patent Profile

✉ Email this page to a colleague

« Back to Dashboard

When do Candesartan Cilexetil And Hydrochlorothiazide patents expire, and what generic alternatives are available?

Candesartan Cilexetil And Hydrochlorothiazide is a drug marketed by Apotex Inc, Macleods Pharms Ltd, Pharmobedient, Prinston Inc, Senores Pharms, and Zydus Lifesciences. and is included in six NDAs.

The generic ingredient in CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE is candesartan cilexetil; hydrochlorothiazide. There are twenty-two drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the candesartan cilexetil; hydrochlorothiazide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Candesartan Cilexetil And Hydrochlorothiazide

A generic version of CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE was approved as candesartan cilexetil; hydrochlorothiazide by PHARMOBEDIENT on December 4^th, 2012.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE?
What are the global sales for CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE?
What is Average Wholesale Price for CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE?

Summary for CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE

US Patents:	0
Applicants:	6
NDAs:	6

US Patents and Regulatory Information for CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE

+ Get email alerts for changes to this table

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Apotex Inc	CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE	candesartan cilexetil; hydrochlorothiazide	TABLET;ORAL	202884-001	Dec 4, 2012		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Zydus Lifesciences	CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE	candesartan cilexetil; hydrochlorothiazide	TABLET;ORAL	203466-003	Nov 27, 2017	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Pharmobedient	CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE	candesartan cilexetil; hydrochlorothiazide	TABLET;ORAL	090704-001	Dec 4, 2012	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Macleods Pharms Ltd	CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE	candesartan cilexetil; hydrochlorothiazide	TABLET;ORAL	204100-001	Feb 27, 2015	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.